Check patentability & draft patents in minutes with Patsnap Eureka AI!

Method for screening h7n9 biomarkers in plasma in vitro and application thereof

A technology of biomarkers and blood plasma, applied in biological testing, biomaterial analysis, material inspection products, etc., can solve the problem of no public reports, no biomarker reports for predicting disease severity and prognosis, severe H7N9 infection High mortality and other problems, to achieve the effect of excellent sensitivity and specificity

Active Publication Date: 2016-08-17
ZHEJIANG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no biomarkers for predicting disease severity and prognosis have been reported
Mortality is high in severe H7N9 infection, and biomarkers to predict disease progression and prognosis in potentially lethal avian influenza infection are urgently needed but have not been published

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for screening h7n9 biomarkers in plasma in vitro and application thereof
  • Method for screening h7n9 biomarkers in plasma in vitro and application thereof
  • Method for screening h7n9 biomarkers in plasma in vitro and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0053] Concrete scheme of the present invention is given by the following examples:

[0054] Determination of Plasma Immune Factors in H7N9 Patients

[0055] (1) Experimental samples

[0056] 1. 46 H7N9 patients, 35 patients within 2 weeks of onset, 80 plasma samples. The average age is 61 years old, including 22 males.

[0057] 2. There were 21 H1N1 patients with an average age of 53.9 years, including 14 males.

[0058] 3. Six control samples were taken from healthy volunteers.

[0059] (2) Experimental materials

[0060]1. Reagents Bio-Plex Pro Human Cytokine Array 27-Plex Group I, 21-Plex Group II, filter paper, 1ml row gun, 200ul row gun, 1ml sterile tip, 200ul sterile tip, 10ul sterile tip 2, instrument Luminex200, horizontal oscillator, magnetic stand, 1.5ml EP tube, 2ml EP tube.

[0061] (3) Experimental steps

[0062] 1. Case collection

[0063] The diagnosis of H7N9 patients can be diagnosed based on epidemiological contact history, clinical manifestations an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for screening H7N9 biomarkers in in-vitro blood plasma, and its application. The method comprises the following steps: 1, preparing blood plasma samples of H7N9 patients; 2, detecting the cytokine and the chemotactic factor of the blood plasma samples to obtain cytokine and chemotactic factor data; 3, comparing the cytokine and the chemotactic factor of H1N1 patients and healthy control blood plasma, and analyzing and processing the data to obtain H7N9 biomarkers; and 4, determining the mortality risk biomarker from the H7N9 biomarkers. An effective H7N9 immune molecular map is established by detecting and analyzing the cytokine and the chemotactic factor of the H7N9 patients from the point of the immune molecule, and the map is used for the in-vitro assessment of the mortality risk of the H7N9 patients. The method has better sensitivity and specificity than traditional detection methods.

Description

technical field [0001] The invention relates to the technical field of biological detection, in particular to new immune markers-plasma cytokines and chemokines of H7N9 patients, which can detect the risk of death of H7N9 patients in vitro. Background technique [0002] Based on the antigenicity of the outer membrane hemagglutinin (H) and neuraminidase (N) proteins of avian influenza A virus, human avian influenza virus has been discovered and identified into 17 H subtypes (H1~H17) and 10 subtypes. N subtype (N1~N10). The above-mentioned H subtypes and N subtypes are combined to form hundreds of different HxNx subtypes of avian influenza A viruses. Birds, especially waterfowl, are generally the natural hosts of these influenza viruses, and they mainly exist and spread in birds. [0003] Before 2013, the H7N9 subtype influenza virus was only found in poultry. There were outbreaks among poultry in the Netherlands, Japan, and the United States, but no human infection was found...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/53
CPCG01N33/54313G01N33/56983G01N2333/11
Inventor 李兰娟郭静陈瑜
Owner ZHEJIANG UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com